Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07279935 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.

Study acronym: REVIVE
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 33 to 32 Eligibility criteria expanded, about 13 wordsv4 Show 1 more changeShow less
    • Eligibility criteria expanded, about 13 words

    See this version in full on ClinicalTrials.gov ↗

  2. Recruitment opened Trial sites expanded: 30 → 33 locations · Start date changed from estimate of May 31, 2026 to May 26, 2026v3 Show 2 more changesShow less
    • Trial sites expanded: 30 → 33 locations
    • Start date changed from estimate of May 31, 2026 to May 26, 2026
  3. Start date: Jan 15, 2026 to May 31, 2026 Site details revised at 2 of 30 sitesv2 Show 1 more changeShow less
    • Site details revised at 2 of 30 sites
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is designed as a multi-cohort trial based on various patient biomarkers study with the potential to include new study treatment in the future. EGFR-sensitive mutation-positive patients with distant recurrence after adjuvant osimertinib treatment for EGFRm resectable SIB-IIIA NSCLC and scheduled to receive osimertinib plus chemotherapy will be enrolled in cohort 1. In this cohort, approximately 100 patients will be recruited from 25 sites in China. The enrolment period is planned to be approximately 16 months.
Trial Details
NCT Number NCT07279935
Lead Sponsor AstraZeneca
Conditions Non-small Cell Lung Cancer
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov